A phase I open-label study evaluated the efficacy and safety of BV at a dose of 1.8 mg/kg every 3 weeks, administered sequentially with CHOP or in combination with CHP (CHOP without vincristine) as frontline treatment in patients with CD30-positive PTCL (NCT01309789). Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.